Last month, Sanofi and Regeneron sued Amgen in a move to fend off a nasty patent court battle over their…More

Eli Lilly & Co.’s Olumiant rejection surprise Friday has one obvious beneficiary: Pfizer and its rival rheumatoid arthritis med, Xeljanz,…More

Anticipating an FDA approval later this year for a promising hereditary angioedema med from CSL, Shire has taken a preemptive…More

Bristol-Myers Squibb’s Opdivo dropped national TV ad spending in March after a bruising battle with a key competitor—Merck’s Keytruda—in February.…More

Roche’s checkpoint inhibitor Tecentriq, which won its initial approval as a treatment for bladder cancer, has now notched an approval…More

Even with a three-month extension, Eli Lilly was unable to quell FDA concerns about the safety risks of its highly…More

Endometriosis affects one in 10 women, but the fact that it’s common doesn’t mean it’s quickly diagnosed—in fact, it can…More

Boston subway riders—make that Boston “T” riders—passing through Kendall Square will be treated to local biopharma banter this month. To…More

A month after scoring a rare victory in a fight to defend the safety of its talcum powder, Johnson & Johnson is…More

Already struggling to meet initial expectations, Sanofi Pasteur’s dengue vaccine Dengvaxia will have to undergo phase 4 testing in Malaysia…More